Novo Nordisk (NYSE:NVO) announced that it is planning to introduce its weight-loss medication Wegovy in vials. “We are ...

The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than ...

A public health expert explains how GLP-1 drugs have changed the way healthcare providers understand and treat obesity.

Compare Zepbound and Wegovy to understand how one hormone vs two impacts weight loss, appetite control, side effects, and ...

It is unclear what the company intends to charge for the vials, the report said. ・Unlike Novo, Eli Lilly and Company already ...

Feb 11 (Reuters) - Novo Nordisk said on Wednesday it plans to launch its weight-loss pill Wegovy in vials. "We are exploring ...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

The oral version of Wegovy has made GLP-1 medicines more accessible and acceptable to many patients who had steered clear of injectable versions, healthcare analytics firm Truveta suggests.

Medications such as Wegovy and Zepbound will no longer be covered for weight loss, although GLP-1 drugs for diabetes will still be approved.

Novo Nordisk says Hims & Hers' drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".